UCMYM-802

N/A

Report date: 2024/03/26 18:01:49

Base Information

Drug NameUCMYM-802

Drug Alias NameUCMYM802UCMYM-802

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Mesothelin

TargetsMesothelin

Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsPancreatic Neoplasms +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesUTC Therapeutics Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPeking University UTC Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursOvarian NeoplasmsPancreatic Neoplasms +[8]

Inactive IndicationsN/A

Other Information

ATC CodeN/A